advertisement
Gazzard G 8
Showing records 1 to 8 | Display all abstracts from Gazzard G100550 Validation of the RCOphth and UKEGS glaucoma risk stratification tool 'GLAUC-STRAT-fast'
Konstantakopoulou E
British Journal of Ophthalmology 2022; 0:
100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Thein AS
American Journal of Ophthalmology 2022; 241: 190-197
100550 Validation of the RCOphth and UKEGS glaucoma risk stratification tool 'GLAUC-STRAT-fast'
Kastner A
British Journal of Ophthalmology 2022; 0:
100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Hedengran A; Azuara-Blanco A
American Journal of Ophthalmology 2022; 241: 190-197
100550 Validation of the RCOphth and UKEGS glaucoma risk stratification tool 'GLAUC-STRAT-fast'
Gazzard G
British Journal of Ophthalmology 2022; 0:
100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Arita R
American Journal of Ophthalmology 2022; 241: 190-197
100550 Validation of the RCOphth and UKEGS glaucoma risk stratification tool 'GLAUC-STRAT-fast'
Jayaram H
British Journal of Ophthalmology 2022; 0:
100646 Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement
Cvenkel B; Gazzard G; Heegaard S; de Paiva CS; Petrovski G; Prokosch-Willing V; Utheim TP; Virgili G; Kolko M
American Journal of Ophthalmology 2022; 241: 190-197